Company: MDCXW
Filing Date: 2025-09-19
Form Type: DRS
Source: 0001062993-25-015719
Chunk: 28

Company: Medicus Pharma Ltd.
Filing Date: 2025-09-19
Form: DRS
Chunk 28
---
 condition or results of operations. To the extent that new or improved pharmaceutical drug treatments are introduced that demonstrate better long-term efficacy and safety, patients and physicians may further delay the introduction of patches, such as SkinJect, if approved, in the skin cancer treatment continuum or delay the use of Teverelix for the treatment of for the treatment of cardiovascular high-risk prostate cancer patients and patients with first AUR episodes due to an enlarged prostate. SkinJect could also face competition from other formulations or devices that deliver chemotherapeutic agents on an extended basis.

Many of our competitors have substantially greater financial, technical and other resources, such as larger research and development staffs and experienced commercial and manufacturing organizations. Mergers and acquisitions in the biotechnology and pharmaceutical industries may result in even more resources being concentrated in competitors. As a result, these companies may obtain regulatory approval more rapidly than we are able and may be more effective in selling and marketing their products as well. Smaller or early-stage companies may also prove to be significant competitors, particularly through collaborative arrangements with large, established companies. Competition may increase further as a result of advances in the commercial applicability of technologies and greater availability of capital for investment in these industries. Our competitors may succeed in developing, acquiring or licensing on an exclusive basis drug products or drug delivery technologies that are more effective or less costly than the Products.

We believe that our ability to compete effectively depends upon many factors both within and beyond our control, including:

the usefulness, ease of use, performance and reliability of our technology compared to our competitors;

the activity and tolerability of the Products, including relative to marketed products and product candidates in development by third parties;

the ability to distinguish safety and efficacy from existing, alternative therapies;

the timing for the Products to complete clinical development and receive market approval;

acceptance of the Products by patients, physicians and other health providers,

our ability to monetize our technology;

the selection of licensing partners for our technology with the necessary skills and resources to drive uptake;

<div align='center'>15

CONFIDENTIAL TREATMENT REQUESTED BY MEDICUS PHARMA LTD.

PURSUANT TO 17 C.F.R. SECTION 200.83</div>

our marketing and selling efforts;

our financial condition and results of operations;

the ability to maintain a good relationship with regulatory authorities;

the price of our future products, including in comparison to branded or generic competitors;

whether coverage and adequate levels of reimbursement are available under private and governmental health insurance plans,

acquisitions or consolidations within our industry